Novo Nordisk reported an updated outlook for its Wegovy oral launch, saying sales and profit will decline less than originally expected due to stronger-than-forecast prescriptions. The company’s guidance change is tied to the fast uptake of its obesity pill in the U.S. market after the product’s entry. The update comes as the obesity category intensifies competition and shifts attention toward oral GLP-1-based regimens. Novo said adjusted sales and adjusted operating profit will drop within a narrower range than it projected earlier, attributing the revision to improved prescription performance. Investors are likely to focus on whether the early prescription strength translates into sustained demand as pricing pressure and payer contracting dynamics continue to develop.